GlassScriptPhysician profile
Ellena Hasley
NPI 1437754439
$6,500.36
in general payments reported to CMS, 2019-2025
16 companies · $2,873 in 2025
The $2,873 reported for 2025 was more than what 96% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $517 · 2022: $387 · 2023: $1,290 · 2024: $1,432 · 2025: $2,873.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,720 · Food and Beverage: $2,671 · Travel and Lodging: $200 · Education: $5.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,720.00 |
| Food and Beverage | $2,670.58 |
| Travel and Lodging | $200.39 |
| Education | $5.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $2,420.86 | 2025 | Jornay Pm |
| Ironshore Pharmaceuticals INC. | $1,156.61 | 2022-2024 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $665.22 | 2021-2025 | Qelbree, Qelbree |
| Corium, LLC | $630.95 | 2022-2025 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $446.23 | 2021-2025 | Trintellix |
| Tris Pharma INC | $401.68 | 2021-2024 | Dyanavel Xr |
| Janssen Pharmaceuticals, INC | $269.46 | 2023-2024 | Spravato |
| Abbvie INC. | $208.56 | 2023-2025 | Vraylar |
| Neos Therapeutics, LP | $115.08 | 2021-2023 | Adzenys Xr-Odt |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $48.36 | 2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $34.52 | 2023-2024 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Avion Pharmaceuticals | $32.13 | 2023 | Dhivy, Methylphenidate Hydrochloride |
| Vertical Pharmaceuticals, LLC | $27.90 | 2025 | Relexxii |
| Sunovion Pharmaceuticals INC. | $20.24 | 2022 | |
| Lundbeck LLC | $14.40 | 2023 | Rexulti |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuronetics, INC. | $8.16 | 2024 | Neurostar Tms Therapy System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ellena Hasley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.